Overview

This symposium will feature an array of translational research programs that integrate computational and experimental approaches to:

1. Discover novel, disease-relevant targets and biomarkers.
2. Develop next-generation animal models and target enabling tools.
3. Support the development of new candidate therapeutics for a diverse portfolio of targets.
4. Advance data-driven drug repositioning and combination therapy development.

The featured programs will include:

• Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) Target Discovery Program and Affiliated Consortia
• Alzheimer’s Gut Microbiome Project
• MODEL- AD Consortium
• TREAT- AD Consortium
• Translational Bioinformatics Program for Drug Repositioning and Combination Therapy Development
• Alzheimer’s Drug Development Program (ADDP)
• Alzheimer’s Clinical Trials Consortium (ACTC)

Agenda

View the agenda.

Target Audience

Academic, biotech and pharmaceutical industry researchers with interest in target and biomarker discovery, preclinical and clinical drug development; computational biologists; data scientists; and open science advocates.

Scheduling Note

Pre-recorded materials will become available on-demand beginning Monday, July 27. A live session will be held on Friday, July 31. All pre-recorded content will be available for 30 days after the conference.